Antibody Therapeutics Market
完整報告名稱與涵蓋範圍
Antibody Therapeutics Market by Product (Commercial, Pipeline), Format (mAb, ADC, Fragment), Target (PDL1, Cytokine), Therapy area (Oncology, Neurology, Inflammatory), Source (Human, Humanized), RoA (IV, SC), Region, Competition - Global Forecast to 2035
報告摘要
The antibody therapeutics market is projected to reach USD 597.1 billion by 2035, up from USD 311.2 billion in 2026, at a CAGR of 7.5% over the forecast period. Market growth is driven by increasing demand for highly targeted biologic therapies across oncology, autoimmune diseases, inflammatory disorders, and other chronic conditions. Monoclonal antibodies remain a major contributor to growth. Advances in antibody engineering are also expanding the market beyond conventional monoclonal antibodies to include bispecific and multispecific antibodies, antibody fragments, and antibody-drug conjugates (ADCs).
By product, the commercialized antibody therapeutics market segment accounted for the largest share of the market in 2025.
The market is segmented into commercialized products (Keytruda, Dupixent, Skyrizi, Darzalex, Vyvgart, and other commercialized products) and pipeline products (Ivonescimab, Sacituzumab tirumotecan (Sac-TMT), Izalontamab brengitecan, and other pipeline products). In 2025, the commercialized antibody therapeutics segment accounted for the largest share of the market, driven by strong clinical adoption and revenue contributions from approved monoclonal antibodies, immune checkpoint inhibitors, anti-inflammatory biologics, ADCs, and bispecific antibodies. This dominance reflects the proven efficacy, target specificity, established safety profiles, and broad use of these therapies across oncology, autoimmune, inflammatory, hematologic, ophthalmic, and rare disease indications.
In 2025, North America accounted for the largest share of the overall antibody therapeutics market.
The US is the largest contributor to North America’s antibody therapeutics market, supported by a dense ecosystem of leading biopharmaceutical companies, academic medical centers, research institutes, clinical-trial networks, and specialized biologics manufacturers. The region benefits from high healthcare spending, strong funding for biologics R&D, early adoption of targeted therapies, and established regulatory pathways that support the development and commercialization of monoclonal antibodies, bispecific antibodies, ADCs, and other next-generation antibody formats.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
• By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%
AbbVie Inc. (US), Merck (US), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron Pharmaceuticals Inc. (US), Boehringer Ingelheim International GmbH (Germany), MacroGenics, Inc. (US), Sanofi (France), Amgen Inc. (US), GlaxoSmithKline plc (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Daiichi Sankyo, Inc. (Japan), AstraZeneca (UK), Celltrion (South Korea), UCB, Inc. (Belgium), Innovent Biologics (China), Emergent BioSolutions Inc. (US), Immunocore Ltd. (UK).
Research Coverage:
This research report categorizes antibody therapeutics market by product (commercialized products, pipeline products), format (monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, antibody drug conjugates), target (PD-1/PD-L1, TNF alpha, cytokine/inflammatory pathway targets, HER2, other targets), source (human, humanized, chimeric, other sources), route of administration (intravenous, subcutaneous, other routes of administration), therapeutic area (autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, other therapeutic areas), end user (hospitals & specialty care centers, long-term care facilities, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the antibody therapeutics market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, products, key strategies, new product launches, acquisitions, and recent developments associated with the antibody therapeutics market. This report also covers the competitive analysis of upcoming startups in the antibody therapeutics market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights into the following:
• Analysis of key drivers (strong approval and pipeline momentum), restraints (long, capital-intensive development), opportunities (expansion beyond oncology), and challenges (safety and post-approval obligations) influencing the growth of the antibody therapeutics market
• Product Approvals: Detailed insights on newly approved products of the antibody therapeutics market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the antibody therapeutics market across varied regions
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the antibody therapeutics market
• Pipeline Analysis: Comprehensive information about antibody therapeutics under clinical trials
• Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including AbbVie Inc. (US), Merck (US), Johnson & Johnson (US), Regeneron Pharmaceuticals Inc. (US), Sanofi (France), Amgen Inc. (US), GlaxoSmithKline plc (UK), among several others, are key players in the antibody therapeutics market
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 STUDY SCOPE 46
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 48
1.3.4 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 49
2 EXECUTIVE SUMMARY 51
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 51
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 52
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 53
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 54
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 55
3 PREMIUM INSIGHTS 56
3.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW 56
3.2 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION & REGION 57
3.3 ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT 58
3.4 ANTIBODY THERAPEUTICS MARKET SHARE, BY SOURCE, 2026 VS. 2035 (%) 58
4 MARKET OVERVIEW 59
4.1 INTRODUCTION 59
4.2 MARKET DYNAMICS 59
4.2.1 DRIVERS 60
4.2.1.1 Rising clinical success and regulatory approvals of antibody therapeutics 60
4.2.1.2 Technological advancements in antibody engineering and bispecific platforms 61
4.2.2 RESTRAINTS 61
4.2.2.1 Patent expirations and biosimilar competition intensifying pricing pressure 61
4.2.3 OPPORTUNITIES 62
4.2.3.1 Expansion of antibody therapeutics into non-oncology therapeutic areas 62
4.2.3.2 Rapid expansion of bispecific and multispecific antibody platforms 62
4.2.4 CHALLENGES 62
4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses 62
4.3 UNMET NEEDS & WHITE SPACES 63
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 63
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 66
5.1.3 BARGAINING POWER OF BUYERS 66
5.1.4 BARGAINING POWER OF SUPPLIERS 66
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 67
5.2.1 INTRODUCTION 67
5.2.2 GDP TRENDS & FORECAST 68
5.2.3 TRENDS IN GLOBAL ANTIBODY THERAPEUTICS MARKET 68
5.3 VALUE CHAIN ANALYSIS 69
5.4 ECOSYSTEM ANALYSIS 70
5.4.1 LIST OF KEY ANTIBODY CDMOS/CMOS & SERVICE PROVIDERS 71
5.4.2 MANUFACTURING SITES & CAPACITY EXPANSION OF KEY ANTIBODY MANUFACTURERS 72
5.5 PRICING ANALYSIS 72
5.5.1 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY KEY PLAYER (2025) 73
5.5.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT (2023–2025) 73
5.5.3 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION (2025) 74
5.6 KEY CONFERENCES & EVENTS, 2026–2027 74
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.8 INVESTMENT/FUNDING ACTIVITY 75
5.9 IMPACT OF 2025 US TARIFFS ON GLOBAL ANTIBODY THERAPEUTICS MARKET 76
5.9.1 INTRODUCTION 76
5.9.2 PRICE IMPACT ANALYSIS 77
5.9.3 IMPACT ON COUNTRY/REGION 77
5.9.3.1 North America 77
5.9.3.2 Europe 78
5.9.3.3 Asia Pacific 78
5.9.4 IMPACT ON END-USE INDUSTRIES 79
5.9.4.1 Hospitals 79
5.9.4.2 Specialty clinics & cancer centers 79
5.9.4.3 Other specialty care settings 79
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS,
AND FUTURE APPLICATIONS 80
6.1 INTRODUCTION 80
6.2 KEY EMERGING TECHNOLOGIES 80
6.2.1 BISPECIFIC & MULTISPECIFIC ANTIBODY ENGINEERING 80
6.2.2 NEXT-GENERATION ANTIBODY–DRUG CONJUGATES (ADCS) 80
6.2.3 FC ENGINEERING & HALF-LIFE EXTENSION 81
6.3 ADJACENT TECHNOLOGIES 81
6.3.1 ANTIBODY DISCOVERY & ENGINEERING PLATFORMS 81
6.3.2 GLYCOENGINEERING & EXPRESSION-SYSTEM ENGINEERING 82
6.4 COMPLEMENTARY TECHNOLOGIES 82
6.4.1 SUBCUTANEOUS DELIVERY & CO-FORMULATION 82
6.4.2 COMPANION DIAGNOSTICS & BIOMARKER-GUIDED PATIENT SELECTION 82
6.5 TECHNOLOGY/PRODUCT ROADMAP 83
6.6 FUTURE APPLICATIONS 83
6.7 PIPELINE ANALYSIS 83
6.7.1 KEY PIPELINE PRODUCTS & INDICATION EXPANSION 84
6.7.2 DISCONTINUED/DEPRIORITIZED PIPELINE ASSETS 85
6.8 IMPACT OF AI/GEN AI ON GLOBAL ANTIBODY THERAPEUTICS MARKET 86
6.8.1 TOP USE CASES & MARKET POTENTIAL 87
6.8.2 CASE STUDIES OF AI IMPLEMENTATION IN GLOBAL ANTIBODY THERAPEUTICS MARKET 87
6.8.3 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS 88
6.8.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN GLOBAL ANTIBODY THERAPEUTICS MARKET 88
7 SUSTAINABILITY & REGULATORY LANDSCAPE 89
7.1 REGIONAL REGULATIONS & COMPLIANCE 89
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT 93
7.1.3 INDUSTRY STANDARDS 96
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 97
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 99
8.1 DECISION-MAKING PROCESS 99
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 100
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
8.2.2 KEY BUYING CRITERIA, BY END USER 100
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
8.4 UNMET NEEDS FROM END USERS 102
8.5 MARKET PROFITABILITY 103
9 ANTIBODY THERAPEUTICS MARKET, BY PRODUCT 104
9.1 INTRODUCTION 105
9.2 COMMERCIALIZED PRODUCTS 105
9.2.1 KEYTRUDA 109
9.2.1.1 Earlier-stage use, combination regimens, and subcutaneous conversion to sustain Keytruda leadership 109
9.2.2 DUPIXENT 113
9.2.2.1 Expansion across type 2 inflammatory diseases and age groups to support continued Dupixent growth 113
9.2.3 SKYRIZI 116
9.2.3.1 Durable IL-23 efficacy and gastroenterology expansion to reinforce Skyrizi adoption 116
9.2.4 DARZALEX 119
9.2.4.1 Frontline combinations and rapid subcutaneous dosing to extend Darzalex franchise 119
9.2.5 VYVGART 122
9.2.5.1 FcRn class expansion and self-administered delivery to accelerate Vyvgart uptake 122
9.2.6 OTHER COMMERCIALIZED PRODUCTS 125
9.3 PIPELINE PRODUCTS 128
9.3.1 IVONESCIMAB 132
9.3.1.1 Dual PD-1/VEGF blockade and broad Phase III development to support Ivonescimab’s global potential 132
9.3.2 SACITUZUMAB TIRUMOTECAN (SAC-TMT) 135
9.3.2.1 TROP2 validation and topoisomerase-I payload activity to drive sac-TMT across solid tumors 135
9.3.3 IZALONTAMAB BRENGITECAN 138
9.3.3.1 Dual EGFR/HER3 targeting and ADC delivery to support iza-bren in resistant epithelial cancers 138
9.3.4 OTHER PIPELINE PRODUCTS 141
10 ANTIBODY THERAPEUTICS MARKET, BY FORMAT 144
10.1 INTRODUCTION 145
10.2 MONOCLONAL ANTIBODIES 145
10.2.1 BROAD CLINICAL VALIDATION AND REPEATED INDICATION EXPANSION TO MAKE MONOCLONAL ANTIBODIES LARGEST FORMAT 145
10.3 POLYCLONAL ANTIBODIES 149
10.3.1 EMERGENCY PREPAREDNESS AND SPECIALIST USE TO SUSTAIN DEMAND FOR POLYCLONAL ANTIBODIES 149
10.4 ANTIBODY FRAGMENTS 152
10.4.1 IMPROVED TISSUE PENETRATION AND LOCAL DELIVERY TO SUPPORT GROWTH OF ANTIBODY FRAGMENTS 152
10.5 BISPECIFIC ANTIBODIES 155
10.5.1 RAPID APPROVALS AND DUAL-TARGET MECHANISMS TO MAKE BISPECIFIC ANTIBODIES HIGH-GROWTH FORMAT 155
10.6 ANTIBODY-DRUG CONJUGATES (ADCS) 158
10.6.1 DM1 161
10.6.1.1 Established HER2 use and regional follow-on products to sustain the DM1 payload segment 161
10.6.2 MMAE 164
10.6.2.1 Broad target applicability and large approved product base to support MMAE growth 164
10.6.3 SN-38 168
10.6.3.1 TROP-2 validation and bystander activity to support continued
SN-38 demand 168
10.6.4 DM4 171
10.6.4.1 Folate receptor-alpha-based patient selection to anchor DM4 payload segment 171
10.6.5 OTHER PAYLOAD TYPES 174
10.7 OTHER ANTIBODY THERAPEUTICS 177
11 ANTIBODY THERAPEUTICS MARKET, BY TARGET 180
11.1 INTRODUCTION 181
11.2 PD-1/PD-L1 181
11.2.1 BROAD ONCOLOGY USE AND COMBINATION STRATEGIES TO SUSTAIN PD-1/PD-L1 DEMAND 181
11.3 TNF ALPHA 185
11.3.1 BIOSIMILAR ACCESS AND ENTRENCHED GUIDELINE USE TO SUSTAIN TNF ALPHA VOLUMES 185
11.4 CYTOKINE/INFLAMMATORY PATHWAY TARGETS 188
11.4.1 INTERLEUKIN AND INFLAMMATORY-PATHWAY EXPANSION TO DRIVE CHRONIC DISEASE ADOPTION 188
11.5 HER2 191
11.5.1 ADC INNOVATION AND BIOMARKER-LED EXPANSION TO STRENGTHEN HER2-TARGETED ANTIBODIES 191
11.6 OTHER TARGETS 194
12 ANTIBODY THERAPEUTICS MARKET, BY SOURCE 197
12.1 INTRODUCTION 198
12.2 HUMAN 198
12.2.1 LOWER IMMUNOGENICITY AND CHRONIC-USE EXPANSION TO SUPPORT FULLY HUMAN ANTIBODIES 198
12.3 HUMANIZED 202
12.3.1 LARGE BLOCKBUSTER BASE AND ENGINEERING FLEXIBILITY TO KEEP HUMANIZED ANTIBODIES DOMINANT 202
12.4 CHIMERIC 205
12.4.1 ESTABLISHED CLINICAL USE AND BIOSIMILAR ACCESS TO SUSTAIN CHIMERIC-ANTIBODY VOLUMES 205
12.5 OTHER SOURCES 208
13 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 211
13.1 INTRODUCTION 212
13.2 INTRAVENOUS 212
13.2.1 COMPLEX ONCOLOGY AND HOSPITAL-BASED DOSING TO MAKE INTRAVENOUS ADMINISTRATION LARGEST ROUTE 212
13.3 SUBCUTANEOUS 216
13.3.1 LOWER ADMINISTRATION BURDEN AND HOME-CARE POTENTIAL TO MAKE SUBCUTANEOUS DELIVERY FASTEST-GROWING ROUTE 216
13.4 OTHER ROUTES OF ADMINISTRATION 219
14 ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA 222
14.1 INTRODUCTION 223
14.2 AUTOIMMUNE & INFLAMMATORY DISEASES 223
14.2.1 CHRONIC DISEASE BURDEN AND TARGETED BIOLOGIC SEQUENCING TO SUSTAIN DEMAND 223
14.3 ONCOLOGY 227
14.3.1 EARLIER-LINE IMMUNOTHERAPY, ADCS, AND BISPECIFICS TO BOOST MARKET GROWTH 227
14.4 HEMATOLOGY 230
14.4.1 DEEPENING RESPONSE EXPECTATIONS AND OUTPATIENT FORMATS TO ACCELERATE HEMATOLOGY ANTIBODY USE 230
14.5 INFECTIOUS DISEASES 233
14.5.1 LONG-ACTING PROPHYLAXIS AND PREPAREDNESS PROGRAMS TO SUPPORT MARKET GROWTH 233
14.6 BONE DISORDER 236
14.6.1 POPULATION AGING, FRACTURE PREVENTION, AND BIOSIMILAR ACCESS TO SUSTAIN DEMAND 236
14.7 IMMUNOLOGY 239
14.7.1 TYPE 2 DISEASE EXPANSION AND BIOMARKER-LED TREATMENT TO DRIVE GROWTH 239
14.8 NEUROLOGY 242
14.8.1 DISEASE-MODIFYING ANTIBODIES AND EASIER ADMINISTRATION TO MAKE NEUROLOGY HIGH-GROWTH AREA 242
14.9 OTHER THERAPEUTIC AREAS 245
15 ANTIBODY THERAPEUTICS MARKET, BY END USER 248
15.1 INTRODUCTION 249
15.2 HOSPITALS & SPECIALTY CARE CENTERS 249
15.2.1 COMPLEX INFUSION PROTOCOLS AND MULTIDISCIPLINARY CARE TO KEEP HOSPITALS AND SPECIALTY CENTERS DOMINANT 249
15.3 LONG-TERM CARE FACILITIES 253
15.3.1 AGING POPULATIONS AND SCHEDULED CHRONIC BIOLOGIC CARE TO SUPPORT GRADUAL LONG-TERM CARE ADOPTION 253
15.4 OTHER END USERS 256
16 ANTIBODY THERAPEUTICS MARKET, BY REGION 259
16.1 INTRODUCTION 260
16.2 NORTH AMERICA 260
16.2.1 US 267
16.2.1.1 Regulatory speed and high-value specialty care to drive market growth 267
16.2.2 CANADA 272
16.2.2.1 Public reimbursement and coordinated cancer care to support steady antibody adoption 272
16.3 EUROPE 277
16.3.1 GERMANY 282
16.3.1.1 AMNOG assessment and dense specialty networks to support high-value antibody use 282
16.3.2 UK 287
16.3.2.1 MHRA agility and NHS specialist pathways to sustain targeted antibody uptake 287
16.3.3 FRANCE 292
16.3.3.1 National HTA, oncology infrastructure, and biologics investment to support market growth 292
16.3.4 ITALY 297
16.3.4.1 AIFA monitoring and hospital oncology networks to enable controlled antibody expansion 297
16.3.5 SPAIN 302
16.3.5.1 Hospital pharmacy expertise and national positioning reports to support measured adoption 302
16.3.6 REST OF EUROPE 307
16.4 ASIA PACIFIC 312
16.4.1 CHINA 318
16.4.1.1 Domestic bispecific and ADC innovation to accelerate antibody market expansion 318
16.4.2 JAPAN 323
16.4.2.1 Universal coverage and first-in-class launches to support stable high-value adoption 323
16.4.3 SOUTH KOREA 328
16.4.3.1 Biologics manufacturing scale and biosimilar leadership to support rapid market development 328
16.4.4 INDIA 333
16.4.4.1 Cost-efficient biosimilars and expanding specialty care to broaden antibody access 333
16.4.5 AUSTRALIA 338
16.4.5.1 Specialist centers and efficient regulation to support adoption of differentiated antibodies 338
16.4.6 REST OF ASIA PACIFIC 343
16.5 LATIN AMERICA 348
16.5.1 BRAZIL 352
16.5.1.1 Large public and private care systems to anchor Latin American antibody demand 352
16.5.2 MEXICO 358
16.5.2.1 Large institutional purchasers and private oncology networks to support rising adoption 358
16.5.3 REST OF LATIN AMERICA 362
16.6 MIDDLE EAST 368
16.6.1 GCC COUNTRIES 372
16.6.1.1 Saudi Arabia 378
16.6.1.1.1 Vision 2030 investment and SFDA modernization to accelerate specialty-biologic access 378
16.6.1.2 UAE 383
16.6.1.2.1 Private insurance, medical hubs, and regulatory reforms to support premium antibody uptake 383
16.6.1.3 Rest of GCC Countries 388
16.6.2 REST OF MIDDLE EAST 392
16.7 AFRICA 396
16.7.1 BIOSIMILARS AND REGIONAL MANUFACTURING INITIATIVES OFFER A PATHWAY TO WIDER ACCESS 396
17 COMPETITIVE LANDSCAPE 402
17.1 INTRODUCTION 402
17.2 KEY STRATEGIES/RIGHT TO WIN 402
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIBODY THERAPEUTICS MARKET 402
17.3 REVENUE ANALYSIS, 2023–2025 404
17.4 MARKET SHARE ANALYSIS, 2025 404
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 406
17.5.1 STARS 406
17.5.2 EMERGING LEADERS 406
17.5.3 PERVASIVE PLAYERS 406
17.5.4 PARTICIPANTS 406
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 408
17.5.5.1 Company footprint 408
17.5.5.2 Region footprint 409
17.5.5.3 Format footprint 410
17.5.5.4 Source footprint 411
17.5.5.5 Route of administration footprint 412
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 413
17.6.1 PROGRESSIVE COMPANIES 413
17.6.2 RESPONSIVE COMPANIES 413
17.6.3 DYNAMIC COMPANIES 413
17.6.4 STARTING BLOCKS 413
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 415
17.6.5.1 Detailed list of key startups/SMEs 415
17.6.5.2 Competitive benchmarking of key startups/SMEs 416
17.7 COMPANY VALUATION & FINANCIAL METRICS 417
17.7.1 COMPANY VALUATION 417
17.7.2 FINANCIAL METRICS 417
17.8 BRAND/PRODUCT COMPARISON 418
17.9 COMPETITIVE SCENARIOS 419
17.9.1 PRODUCT APPROVALS 419
17.9.2 DEALS 420
17.9.3 OTHER DEVELOPMENTS 420
18 COMPANY PROFILES 421
18.1 KEY PLAYERS 421
18.1.1 F. HOFFMANN-LA ROCHE LTD. 421
18.1.1.1 Business overview 421
18.1.1.2 Products offered 423
18.1.1.3 Recent developments 424
18.1.1.3.1 Product approvals 424
18.1.1.3.2 Deals 425
18.1.1.3.3 Expansions 426
18.1.1.4 MnM view 426
18.1.1.4.1 Key strengths 426
18.1.1.4.2 Strategic choices 426
18.1.1.4.3 Weaknesses & competitive threats 426
18.1.2 ABBVIE INC. 427
18.1.2.1 Business overview 427
18.1.2.2 Products offered 429
18.1.2.3 Recent developments 429
18.1.2.3.1 Product approvals 429
18.1.2.3.2 Deals 430
18.1.2.3.3 Expansions 431
18.1.2.4 MnM view 431
18.1.2.4.1 Key strengths 431
18.1.2.4.2 Strategic choices 431
18.1.2.4.3 Weaknesses & competitive threats 431
18.1.3 AMGEN INC. 432
18.1.3.1 Business overview 432
18.1.3.2 Products offered 434
18.1.3.3 Recent developments 434
18.1.3.3.1 Product approvals 434
18.1.3.3.2 Deals 435
18.1.3.3.3 Expansions 436
18.1.3.4 MnM view 436
18.1.3.4.1 Key strengths 436
18.1.3.4.2 Strategic choices 436
18.1.3.4.3 Weaknesses & competitive threats 436
18.1.4 REGENERON PHARMACEUTICALS, INC. 437
18.1.4.1 Business overview 437
18.1.4.2 Products offered 438
18.1.4.3 Recent developments 439
18.1.4.3.1 Product approvals 439
18.1.4.3.2 Deals 439
18.1.4.3.3 Expansions 440
18.1.4.4 MnM view 440
18.1.4.4.1 Key strengths 440
18.1.4.4.2 Strategic choices 440
18.1.4.4.3 Weaknesses & competitive threats 440
18.1.5 ASTRAZENECA PLC 441
18.1.5.1 Business overview 441
18.1.5.2 Products offered 442
18.1.5.3 Recent developments 443
18.1.5.3.1 Product approvals 443
18.1.5.3.2 Deals 443
18.1.5.3.3 Expansions 444
18.1.5.4 MnM view 444
18.1.5.4.1 Key strengths 444
18.1.5.4.2 Strategic choices 444
18.1.5.4.3 Weaknesses & competitive threats 444
18.1.6 BIOGEN INC. 445
18.1.6.1 Business overview 445
18.1.6.2 Products offered 447
18.1.6.3 Recent developments 447
18.1.6.3.1 Product approvals 447
18.1.6.3.2 Deals 448
18.1.6.3.3 Expansions 448
18.1.6.4 MnM view 449
18.1.6.4.1 Key strengths 449
18.1.6.4.2 Strategic choices 449
18.1.6.4.3 Weaknesses & competitive threats 449
18.1.7 MERCK & CO., INC. 450
18.1.7.1 Business overview 450
18.1.7.2 Products offered 451
18.1.7.3 Recent developments 452
18.1.7.3.1 Product approvals 452
18.1.7.3.2 Deals 452
18.1.7.4 MnM view 453
18.1.7.4.1 Key strengths 453
18.1.7.4.2 Strategic choices 453
18.1.7.4.3 Weaknesses & competitive threats 453
18.1.8 NOVARTIS AG 454
18.1.8.1 Business overview 454
18.1.8.2 Products offered 455
18.1.8.3 Recent developments 456
18.1.8.3.1 Product approvals 456
18.1.8.3.2 Deals 456
18.1.8.4 MnM view 456
18.1.8.4.1 Key strengths 456
18.1.8.4.2 Strategic choices 456
18.1.8.4.3 Weaknesses & competitive threats 456
18.1.9 DAIICHI SANKYO COMPANY, LIMITED 457
18.1.9.1 Business overview 457
18.1.9.2 Products offered 459
18.1.9.3 Recent developments 459
18.1.9.3.1 Product approvals 459
18.1.9.3.2 Deals 460
18.1.10 GSK PLC 461
18.1.10.1 Business overview 461
18.1.10.2 Products offered 462
18.1.10.3 Recent developments 463
18.1.10.3.1 Product approvals 463
18.1.11 SANOFI 464
18.1.11.1 Business overview 464
18.1.11.2 Products offered 465
18.1.11.3 Recent developments 466
18.1.11.3.1 Product approvals 466
18.1.11.3.2 Deals 466
18.1.12 GILEAD SCIENCES, INC. 467
18.1.12.1 Business overview 467
18.1.12.2 Products offered 468
18.1.12.3 Recent developments 469
18.1.12.3.1 Product approvals 469
18.1.13 JAZZ PHARMACEUTICALS PLC 470
18.1.13.1 Business overview 470
18.1.13.2 Products offered 471
18.1.13.3 Recent developments 472
18.1.13.3.1 Product approvals 472
18.1.13.3.2 Deals 472
18.1.14 PFIZER INC. 473
18.1.14.1 Business overview 473
18.1.14.2 Products offered 474
18.1.14.3 Recent developments 475
18.1.14.3.1 Product approvals 475
18.1.14.3.2 Deals 475
18.1.15 JOHNSON & JOHNSON 476
18.1.15.1 Business overview 476
18.1.15.2 Products offered 477
18.1.15.3 Recent developments 478
18.1.15.3.1 Product approvals 478
18.1.15.3.2 Deals 478
18.1.16 ELI LILLY AND COMPANY 479
18.1.16.1 Business overview 479
18.1.16.2 Products offered 480
18.1.16.3 Recent developments 481
18.1.16.3.1 Product approvals 481
18.1.16.3.2 Expansions 481
18.1.17 H. LUNDBECK A/S 482
18.1.17.1 Business overview 482
18.1.17.2 Products offered 483
18.1.17.3 Recent developments 483
18.1.17.3.1 Product approvals 483
18.2 OTHER PLAYERS 484
18.2.1 CHUGAI PHARMACEUTICAL CO., LTD. 484
18.2.2 AKESO, INC. 485
18.2.3 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. 486
18.2.4 CELLTRION, INC. 488
18.2.5 CSL BEHRING 489
18.2.6 OTSUKA AMERICA PHARMACEUTICAL, INC. 490
18.2.7 LEPU BIOPHARMA CO., LTD. 491
18.2.8 SINOCELLTECH GROUP LTD. 492
18.2.9 SYNERMORE BIOLOGICS 493
18.2.10 SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 494
18.2.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 495
19 RESEARCH METHODOLOGY 497
19.1 RESEARCH DATA 497
19.1.1 SECONDARY DATA 498
19.1.2 PRIMARY DATA 498
19.2 MARKET ESTIMATION METHODOLOGY 500
19.2.1 MARKET SIZE ESTIMATION 500
19.2.2 INSIGHTS FROM PRIMARY EXPERTS 502
19.2.3 BOTTOM-UP APPROACH 503
19.3 MARKET GROWTH RATE PROJECTIONS 504
19.4 MARKET BREAKDOWN & DATA TRIANGULATION 505
19.5 RESEARCH ASSUMPTIONS 506
19.6 RESEARCH LIMITATIONS 507
19.7 RISK ANALYSIS 507
20 APPENDIX 508
20.1 DISCUSSION GUIDE 508
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 513
20.3 CUSTOMIZATION OPTIONS 515
20.4 RELATED REPORTS 515
20.5 AUTHOR DETAILS 516
圖表清單 List of Tables & Figures
TABLE 1 ANTIBODY THERAPEUTICS MARKET: INCLUSIONS & EXCLUSIONS 48
TABLE 2 GLOBAL ANTIBODY THERAPEUTICS MARKET: IMPACT ANALYSIS 60
TABLE 3 GLOBAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 66
TABLE 4 GLOBAL ANTIBODY THERAPEUTICS MARKET: KEY ANTIBODY CDMOS/CMOS & SERVICE PROVIDERS 71
TABLE 5 GLOBAL ANTIBODY THERAPEUTICS MARKET: MANUFACTURING SITES & CAPACITY EXPANSION OF KEY ANTIBODY MANUFACTURERS 72
TABLE 6 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY KEY PLAYER (2025) 73
TABLE 7 INDICATIVE PRICE TREND DATA, BY PRODUCT (2023–2025) 73
TABLE 8 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION (2025) 74
TABLE 9 GLOBAL ANTIBODY THERAPEUTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 & EVENTS, 2026–2027 74
TABLE 10 GLOBAL ANTIBODY THERAPEUTICS MARKET: PIPELINE ANALYSIS 84
TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN GLOBAL ANTIBODY
THERAPEUTICS MARKET 87
TABLE 12 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN GLOBAL ANTIBODY THERAPEUTICS MARKET 88
TABLE 13 REGULATORY APPROVAL PATHWAYS, BY ANTIBODY FORMAT 89
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 90
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 91
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 18 REIMBURSEMENT SCENARIO 94
TABLE 19 COUNTRY-WISE REGULATORY SCENARIO FOR ANTIBODY THERAPEUTICS MANUFACTURERS 96
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 100
TABLE 21 KEY BUYING CRITERIA, BY END USER 101
TABLE 22 ANTIBODY THERAPEUTICS MARKET, BY PRODUCT, 2024–2035 (USD BILLION) 105
TABLE 23 COMMERCIALIZED ANTIBODY PRODUCTS MARKET, BY REGION,
2024–2035 (USD BILLION) 106
TABLE 24 NORTH AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 106
TABLE 25 EUROPE: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 107
TABLE 26 ASIA PACIFIC: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 107
TABLE 27 LATIN AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 108
TABLE 28 MIDDLE EAST: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY REGION, 2024–2035 (USD BILLION) 108
TABLE 29 GCC COUNTRIES: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 108
TABLE 30 COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 109
TABLE 31 KEYTRUDA MARKET, BY REGION, 2024–2035 (USD BILLION) 110
TABLE 32 NORTH AMERICA: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 110
TABLE 33 EUROPE: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 111
TABLE 34 ASIA PACIFIC: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 111
TABLE 35 LATIN AMERICA: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 112
TABLE 36 MIDDLE EAST: KEYTRUDA MARKET, BY REGION, 2024–2035 (USD BILLION) 112
TABLE 37 GCC COUNTRIES: KEYTRUDA MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 112
TABLE 38 DUPIXENT MARKET, BY REGION, 2024–2035 (USD BILLION) 113
TABLE 39 NORTH AMERICA: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 113
TABLE 40 EUROPE: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 114
TABLE 41 ASIA PACIFIC: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 114
TABLE 42 LATIN AMERICA: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 115
TABLE 43 MIDDLE EAST: DUPIXENT MARKET, BY REGION, 2024–2035 (USD BILLION) 115
TABLE 44 GCC COUNTRIES: DUPIXENT MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 115
TABLE 45 SKYRIZI MARKET, BY REGION, 2024–2035 (USD BILLION) 116
TABLE 46 NORTH AMERICA: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 116
TABLE 47 EUROPE: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 117
TABLE 48 ASIA PACIFIC: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 117
TABLE 49 LATIN AMERICA: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 118
TABLE 50 MIDDLE EAST: SKYRIZI MARKET, BY REGION, 2024–2035 (USD BILLION) 118
TABLE 51 GCC COUNTRIES: SKYRIZI MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 118
TABLE 52 DARZALEX MARKET, BY REGION, 2024–2035 (USD BILLION) 119
TABLE 53 NORTH AMERICA: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 119
TABLE 54 EUROPE: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 120
TABLE 55 ASIA PACIFIC: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 120
TABLE 56 LATIN AMERICA: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 121
TABLE 57 MIDDLE EAST: DARZALEX MARKET, BY REGION, 2024–2035 (USD BILLION) 121
TABLE 58 GCC COUNTRIES: DARZALEX MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 121
TABLE 59 VYVGART MARKET, BY REGION, 2024–2035 (USD BILLION) 122
TABLE 60 NORTH AMERICA: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 122
TABLE 61 EUROPE: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 123
TABLE 62 ASIA PACIFIC: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 123
TABLE 63 LATIN AMERICA: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 124
TABLE 64 MIDDLE EAST: VYVGART MARKET, BY REGION, 2024–2035 (USD BILLION) 124
TABLE 65 GCC COUNTRIES: VYVGART MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 124
TABLE 66 OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY REGION, 2024–2035 (USD BILLION) 125
TABLE 67 NORTH AMERICA: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 125
TABLE 68 EUROPE: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 126
TABLE 69 ASIA PACIFIC: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 126
TABLE 70 LATIN AMERICA: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 127
TABLE 71 MIDDLE EAST: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY REGION, 2024–2035 (USD BILLION) 127
TABLE 72 GCC COUNTRIES: OTHER COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 127
TABLE 73 PIPELINE ANTIBODY PRODUCTS MARKET, BY REGION, 2024–2035 (USD BILLION) 128
TABLE 74 NORTH AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 128
TABLE 75 EUROPE: PIPELINE ANTIBODY PRODUCTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 129
TABLE 76 ASIA PACIFIC: PIPELINE ANTIBODY PRODUCTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 129
TABLE 77 LATIN AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 130
TABLE 78 MIDDLE EAST: PIPELINE ANTIBODY PRODUCTS MARKET,
BY REGION, 2024–2035 (USD BILLION) 130
TABLE 79 GCC COUNTRIES: PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 131
TABLE 80 PIPELINE ANTIBODY PRODUCTS MARKET, BY TYPE, 2024–2035 (USD BILLION) 131
TABLE 81 IVONESCIMAB MARKET, BY REGION, 2024–2035 (USD BILLION) 132
TABLE 82 NORTH AMERICA: IVONESCIMAB MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 132
TABLE 83 EUROPE: IVONESCIMAB MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 133
TABLE 84 ASIA PACIFIC: IVONESCIMAB MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 133
TABLE 85 LATIN AMERICA: IVONESCIMAB MARKET, BY COUNTRY, 2024–2035 (USD BILLION) 134
TABLE 86 MIDDLE EAST: IVONESCIMAB MARKET, BY REGION, 2024–2035 (USD BILLION) 134
TABLE 87 GCC COUNTRIES: IVONESCIMAB MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 134
TABLE 88 SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET, BY REGION,
2024–2035 (USD BILLION) 135
TABLE 89 NORTH AMERICA: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 135
TABLE 90 EUROPE: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 136
TABLE 91 ASIA PACIFIC: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 136
TABLE 92 LATIN AMERICA: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 137
TABLE 93 MIDDLE EAST: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,
BY REGION, 2024–2035 (USD BILLION) 137
TABLE 94 GCC COUNTRIES: SACITUZUMAB TIRUMOTECAN (SAC-TMT) MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 137
TABLE 95 IZALONTAMAB BRENGITECAN MARKET, BY REGION, 2024–2035 (USD BILLION) 138
TABLE 96 NORTH AMERICA: IZALONTAMAB BRENGITECAN MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 138
TABLE 97 EUROPE: IZALONTAMAB BRENGITECAN MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 139
TABLE 98 ASIA PACIFIC: IZALONTAMAB BRENGITECAN MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 139
TABLE 99 LATIN AMERICA: IZALONTAMAB BRENGITECAN MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 140
TABLE 100 MIDDLE EAST: IZALONTAMAB BRENGITECAN MARKET,
BY REGION, 2024–2035 (USD BILLION) 140
TABLE 101 GCC COUNTRIES: IZALONTAMAB BRENGITECAN MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 140
TABLE 102 OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY REGION, 2024–2035 (USD BILLION) 141
TABLE 103 NORTH AMERICA: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 141
TABLE 104 EUROPE: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 142
TABLE 105 ASIA PACIFIC: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 142
TABLE 106 LATIN AMERICA: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 143
TABLE 107 MIDDLE EAST: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY REGION, 2024–2035 (USD BILLION) 143
TABLE 108 GCC COUNTRIES: OTHER PIPELINE ANTIBODY PRODUCTS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 143
TABLE 109 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2024–2035 (USD BILLION) 145
TABLE 110 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2035 (USD BILLION) 146
TABLE 111 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 146
TABLE 112 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 147
TABLE 113 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 147
TABLE 114 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 148
TABLE 115 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY REGION,
2024–2035 (USD BILLION) 148
TABLE 116 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 148
TABLE 117 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2035 (USD BILLION) 149
TABLE 118 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 149
TABLE 119 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 150
TABLE 120 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 150
TABLE 121 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 151
TABLE 122 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY REGION,
2024–2035 (USD BILLION) 151
TABLE 123 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 151
TABLE 124 ANTIBODY FRAGMENTS MARKET, BY REGION, 2024–2035 (USD BILLION) 152
TABLE 125 NORTH AMERICA: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 152
TABLE 126 EUROPE: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 153
TABLE 127 ASIA PACIFIC: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 153
TABLE 128 LATIN AMERICA: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 154
TABLE 129 MIDDLE EAST: ANTIBODY FRAGMENTS MARKET, BY REGION,
2024–2035 (USD BILLION) 154
TABLE 130 GCC COUNTRIES: ANTIBODY FRAGMENTS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 154
TABLE 131 BISPECIFIC ANTIBODIES MARKET, BY REGION, 2024–2035 (USD BILLION) 155
TABLE 132 NORTH AMERICA: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 155
TABLE 133 EUROPE: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 156
TABLE 134 ASIA PACIFIC: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 156
TABLE 135 LATIN AMERICA: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 157
TABLE 136 MIDDLE EAST: BISPECIFIC ANTIBODIES MARKET, BY REGION,
2024–2035 (USD BILLION) 157
TABLE 137 GCC COUNTRIES: BISPECIFIC ANTIBODIES MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 157
TABLE 138 ANTIBODY-DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD BILLION) 158
TABLE 139 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 158
TABLE 140 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 159
TABLE 141 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 159
TABLE 142 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 160
TABLE 143 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET,
BY REGION, 2024–2035 (USD BILLION) 160
TABLE 144 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 160
TABLE 145 ANTIBODY-DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,
2024–2035 (USD BILLION) 161
TABLE 146 ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 161
TABLE 147 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 162
TABLE 148 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 162
TABLE 149 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 163
TABLE 150 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 163
TABLE 151 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 164
TABLE 152 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR DM1 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 164
TABLE 153 ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 165
TABLE 154 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD, BY COUNTRY, 2024–2035 (USD BILLION) 165
TABLE 155 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 166
TABLE 156 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 166
TABLE 157 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 167
TABLE 158 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 167
TABLE 159 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR MMAE PAYLOAD, BY COUNTRY, 2024–2035 (USD BILLION) 167
TABLE 160 ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 168
TABLE 161 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD, BY COUNTRY, 2024–2035 (USD BILLION) 168
TABLE 162 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 169
TABLE 163 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 169
TABLE 164 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 170
TABLE 165 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 170
TABLE 166 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR SN-38 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 170
TABLE 167 ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 171
TABLE 168 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 171
TABLE 169 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 172
TABLE 170 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 172
TABLE 171 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 173
TABLE 172 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY REGION, 2024–2035 (USD BILLION) 173
TABLE 173 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR DM4 PAYLOAD,
BY COUNTRY, 2024–2035 (USD BILLION) 173
TABLE 174 ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES,
BY REGION, 2024–2035 (USD BILLION) 174
TABLE 175 NORTH AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 174
TABLE 176 EUROPE: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES,
BY COUNTRY, 2024–2035 (USD BILLION) 175
TABLE 177 ASIA PACIFIC: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 175
TABLE 178 LATIN AMERICA: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 176
TABLE 179 MIDDLE EAST: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY REGION, 2024–2035 (USD BILLION) 176
TABLE 180 GCC COUNTRIES: ANTIBODY-DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2024–2035 (USD BILLION) 176
TABLE 181 OTHER ANTIBODY THERAPEUTICS MARKET, BY REGION,
2024–2035 (USD BILLION) 177
TABLE 182 NORTH AMERICA: OTHER ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 177
TABLE 183 EUROPE: OTHER ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 178
TABLE 184 ASIA PACIFIC: OTHER ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 178
TABLE 185 LATIN AMERICA: OTHER ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 179
TABLE 186 MIDDLE EAST: OTHER ANTIBODY THERAPEUTICS MARKET,
BY REGION, 2024–2035 (USD BILLION) 179
TABLE 187 GCC COUNTRIES: OTHER ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 179
TABLE 188 ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 181
TABLE 189 ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,
BY REGION, 2024–2035 (USD BILLION) 182
TABLE 190 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 182
TABLE 191 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 183
TABLE 192 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 183
TABLE 193 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 184
TABLE 194 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS,
BY REGION, 2024–2035 (USD BILLION) 184
TABLE 195 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR PD-1/PD-L1 TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 184
TABLE 196 ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,
BY REGION, 2024–2035 (USD BILLION) 185
TABLE 197 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 185
TABLE 198 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 186
TABLE 199 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 186
TABLE 200 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 187
TABLE 201 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,
BY REGION, 2024–2035 (USD BILLION) 187
TABLE 202 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR TNF ALPHA TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 187
TABLE 203 ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY REGION, 2024–2035 (USD BILLION) 188
TABLE 204 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY,
2024–2035 (USD BILLION) 188
TABLE 205 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 189
TABLE 206 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY, 2024–2035 (USD BILLION) 189
TABLE 207 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY,
2024–2035 (USD BILLION) 190
TABLE 208 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY REGION, 2024–2035 (USD BILLION) 190
TABLE 209 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR CYTOKINE/INFLAMMATORY PATHWAY TARGETS, BY COUNTRY,
2024–2035 (USD BILLION) 190
TABLE 210 ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY REGION, 2024–2035 (USD BILLION) 191
TABLE 211 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 191
TABLE 212 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 192
TABLE 213 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 192
TABLE 214 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 193
TABLE 215 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY REGION, 2024–2035 (USD BILLION) 193
TABLE 216 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HER2 TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 193
TABLE 217 ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY REGION, 2024–2035 (USD BILLION) 194
TABLE 218 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 194
TABLE 219 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 195
TABLE 220 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 195
TABLE 221 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 196
TABLE 222 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY REGION, 2024–2035 (USD BILLION) 196
TABLE 223 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER TARGETS,
BY COUNTRY, 2024–2035 (USD BILLION) 196
TABLE 224 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024–2035 (USD BILLION) 198
TABLE 225 ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY REGION, 2024–2035 (USD BILLION) 199
TABLE 226 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 199
TABLE 227 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 200
TABLE 228 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 200
TABLE 229 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 201
TABLE 230 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY REGION, 2024–2035 (USD BILLION) 201
TABLE 231 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 201
TABLE 232 ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,
BY REGION, 2024–2035 (USD BILLION) 202
TABLE 233 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2024–2035 (USD BILLION) 202
TABLE 234 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 203
TABLE 235 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 203
TABLE 236 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2024–2035 (USD BILLION) 204
TABLE 237 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES,
BY REGION, 2024–2035 (USD BILLION) 204
TABLE 238 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2024–2035 (USD BILLION) 204
TABLE 239 ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY REGION, 2024–2035 (USD BILLION) 205
TABLE 240 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 205
TABLE 241 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 206
TABLE 242 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 206
TABLE 243 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 207
TABLE 244 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY REGION, 2024–2035 (USD BILLION) 207
TABLE 245 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 207
TABLE 246 ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY REGION, 2024–2035 (USD BILLION) 208
TABLE 247 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 208
TABLE 248 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 209
TABLE 249 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 209
TABLE 250 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 210
TABLE 251 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY REGION, 2024–2035 (USD BILLION) 210
TABLE 252 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES,
BY COUNTRY, 2024–2035 (USD BILLION) 210
TABLE 253 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2035 (USD BILLION) 212
TABLE 254 ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 213
TABLE 255 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 213
TABLE 256 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 214
TABLE 257 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 214
TABLE 258 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 215
TABLE 259 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 215
TABLE 260 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 215
TABLE 261 ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 216
TABLE 262 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 216
TABLE 263 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 217
TABLE 264 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 217
TABLE 265 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 218
TABLE 266 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 218
TABLE 267 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 218
TABLE 268 ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2024–2035 (USD BILLION) 219
TABLE 269 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 219
TABLE 270 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 220
TABLE 271 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 220
TABLE 272 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 221
TABLE 273 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2024–2035 (USD BILLION) 221
TABLE 274 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2035 (USD BILLION) 221
TABLE 275 ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 223
TABLE 276 ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024–2035 (USD BILLION) 224
TABLE 277 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 224
TABLE 278 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 225
TABLE 279 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 225
TABLE 280 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 226
TABLE 281 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024–2035 (USD BILLION) 226
TABLE 282 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 226
TABLE 283 ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY REGION, 2024–2035 (USD BILLION) 227
TABLE 284 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 227
TABLE 285 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 228
TABLE 286 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 228
TABLE 287 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 229
TABLE 288 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY REGION, 2024–2035 (USD BILLION) 229
TABLE 289 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 229
TABLE 290 ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY REGION, 2024–2035 (USD BILLION) 230
TABLE 291 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 230
TABLE 292 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 231
TABLE 293 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 231
TABLE 294 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 232
TABLE 295 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY REGION, 2024–2035 (USD BILLION) 232
TABLE 296 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 232
TABLE 297 ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2024–2035 (USD BILLION) 233
TABLE 298 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 233
TABLE 299 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2035 (USD BILLION) 234
TABLE 300 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2035 (USD BILLION) 234
TABLE 301 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 235
TABLE 302 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2024–2035 (USD BILLION) 235
TABLE 303 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2035 (USD BILLION) 235
TABLE 304 ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY REGION, 2024–2035 (USD BILLION) 236
TABLE 305 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY COUNTRY, 2024–2035 (USD BILLION) 236
TABLE 306 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY COUNTRY, 2024–2035 (USD BILLION) 237
TABLE 307 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY COUNTRY, 2024–2035 (USD BILLION) 237
TABLE 308 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY COUNTRY, 2024–2035 (USD BILLION) 238
TABLE 309 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY REGION, 2024–2035 (USD BILLION) 238
TABLE 310 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR BONE DISORDER,
BY COUNTRY, 2024–2035 (USD BILLION) 238
TABLE 311 ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY REGION, 2024–2035 (USD BILLION) 239
TABLE 312 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 239
TABLE 313 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 240
TABLE 314 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 240
TABLE 315 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 241
TABLE 316 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY REGION, 2024–2035 (USD BILLION) 241
TABLE 317 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 241
TABLE 318 ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY REGION, 2024–2035 (USD BILLION) 242
TABLE 319 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 242
TABLE 320 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 243
TABLE 321 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 243
TABLE 322 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 244
TABLE 323 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY REGION, 2024–2035 (USD BILLION) 244
TABLE 324 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2035 (USD BILLION) 244
TABLE 325 ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2024–2035 (USD BILLION) 245
TABLE 326 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2035 (USD BILLION) 245
TABLE 327 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2024–2035 (USD BILLION) 246
TABLE 328 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2035 (USD BILLION) 246
TABLE 329 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2035 (USD BILLION) 247
TABLE 330 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2035 (USD BILLION) 247
TABLE 331 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2035 (USD BILLION) 247
TABLE 332 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024–2035 (USD BILLION) 249
TABLE 333 ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY REGION, 2024–2035 (USD BILLION) 250
TABLE 334 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY COUNTRY, 2024–2035 (USD BILLION) 250
TABLE 335 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY COUNTRY, 2024–2035 (USD BILLION) 251
TABLE 336 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY COUNTRY, 2024–2035 (USD BILLION) 251
TABLE 337 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY COUNTRY, 2024–2035 (USD BILLION) 252
TABLE 338 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY REGION, 2024–2035 (USD BILLION) 252
TABLE 339 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS & SPECIALTY CARE CENTERS, BY COUNTRY, 2024–2035 (USD BILLION) 252
TABLE 340 ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2035 (USD BILLION) 253
TABLE 341 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2035 (USD BILLION) 253
TABLE 342 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2035 (USD BILLION) 254
TABLE 343 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2035 (USD BILLION) 254
TABLE 344 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2035 (USD BILLION) 255
TABLE 345 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2035 (USD BILLION) 255
TABLE 346 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2035 (USD BILLION) 255
TABLE 347 ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY REGION, 2024–2035 (USD BILLION) 256
TABLE 348 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD BILLION) 256
TABLE 349 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD BILLION) 257
TABLE 350 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD BILLION) 257
TABLE 351 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD BILLION) 258
TABLE 352 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY REGION, 2024–2035 (USD BILLION) 258
TABLE 353 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2035 (USD BILLION) 258
TABLE 354 ANTIBODY THERAPEUTICS MARKET, BY REGION, 2024–2035 (USD BILLION) 260
TABLE 355 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 261
TABLE 356 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 262
TABLE 357 NORTH AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 262
TABLE 358 NORTH AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 263
TABLE 359 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 263
TABLE 360 NORTH AMERICA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 264
TABLE 361 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 264
TABLE 362 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 265
TABLE 363 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 265
TABLE 364 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 266
TABLE 365 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 266
TABLE 366 US: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT, 2024–2035 (USD BILLION) 267
TABLE 367 US: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 267
TABLE 368 US: PIPELINE ANTIBODY PRODUCTS MARKET, BY TYPE, 2024–2035 (USD BILLION) 268
TABLE 369 US: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2024–2035 (USD BILLION) 268
TABLE 370 US: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 269
TABLE 371 US: ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 269
TABLE 372 US: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024–2035 (USD BILLION) 270
TABLE 373 US: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2035 (USD BILLION) 270
TABLE 374 US: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 271
TABLE 375 US: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024–2035 (USD BILLION) 271
TABLE 376 CANADA: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 272
TABLE 377 CANADA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 272
TABLE 378 CANADA: PIPELINE ANTIBODY PRODUCTS MARKET, BY TYPE,
2024–2035 (USD BILLION) 273
TABLE 379 CANADA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 273
TABLE 380 CANADA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 274
TABLE 381 CANADA: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 274
TABLE 382 CANADA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 275
TABLE 383 CANADA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 275
TABLE 384 CANADA: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 276
TABLE 385 CANADA: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 276
TABLE 386 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 277
TABLE 387 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 277
TABLE 388 EUROPE: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 278
TABLE 389 EUROPE: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 278
TABLE 390 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 279
TABLE 391 EUROPE: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 279
TABLE 392 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 280
TABLE 393 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 280
TABLE 394 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 280
TABLE 395 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 281
TABLE 396 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 281
TABLE 397 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 282
TABLE 398 GERMANY: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 282
TABLE 399 GERMANY: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 283
TABLE 400 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 283
TABLE 401 GERMANY: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 284
TABLE 402 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 284
TABLE 403 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 285
TABLE 404 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 285
TABLE 405 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 286
TABLE 406 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 286
TABLE 407 UK: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT, 2024–2035 (USD BILLION) 287
TABLE 408 UK: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 287
TABLE 409 UK: PIPELINE ANTIBODY PRODUCTS MARKET, BY TYPE, 2024–2035 (USD BILLION) 288
TABLE 410 UK: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2024–2035 (USD BILLION) 288
TABLE 411 UK: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 289
TABLE 412 UK: ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 289
TABLE 413 UK: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024–2035 (USD BILLION) 290
TABLE 414 UK: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2035 (USD BILLION) 290
TABLE 415 UK: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 291
TABLE 416 UK: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024–2035 (USD BILLION) 291
TABLE 417 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 292
TABLE 418 FRANCE: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 292
TABLE 419 FRANCE: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 293
TABLE 420 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 293
TABLE 421 FRANCE: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 294
TABLE 422 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 294
TABLE 423 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 295
TABLE 424 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 295
TABLE 425 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 296
TABLE 426 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 296
TABLE 427 ITALY: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 297
TABLE 428 ITALY: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 297
TABLE 429 ITALY: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 298
TABLE 430 ITALY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 298
TABLE 431 ITALY: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 299
TABLE 432 ITALY: ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 299
TABLE 433 ITALY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 300
TABLE 434 ITALY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2035 (USD BILLION) 300
TABLE 435 ITALY: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 301
TABLE 436 ITALY: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 301
TABLE 437 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 302
TABLE 438 SPAIN: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 302
TABLE 439 SPAIN: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 303
TABLE 440 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 303
TABLE 441 SPAIN: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 304
TABLE 442 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 304
TABLE 443 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 305
TABLE 444 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 305
TABLE 445 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 306
TABLE 446 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 306
TABLE 447 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 307
TABLE 448 REST OF EUROPE: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 307
TABLE 449 REST OF EUROPE: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 308
TABLE 450 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 308
TABLE 451 REST OF EUROPE: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 309
TABLE 452 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 309
TABLE 453 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 310
TABLE 454 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 310
TABLE 455 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 311
TABLE 456 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 311
TABLE 457 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 313
TABLE 458 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 313
TABLE 459 ASIA PACIFIC: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 314
TABLE 460 ASIA PACIFIC: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 314
TABLE 461 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 315
TABLE 462 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 315
TABLE 463 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 316
TABLE 464 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 316
TABLE 465 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 317
TABLE 466 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 317
TABLE 467 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 318
TABLE 468 CHINA: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 318
TABLE 469 CHINA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 319
TABLE 470 CHINA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 319
TABLE 471 CHINA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 320
TABLE 472 CHINA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 320
TABLE 473 CHINA: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 321
TABLE 474 CHINA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 321
TABLE 475 CHINA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 321
TABLE 476 CHINA: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 322
TABLE 477 CHINA: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 322
TABLE 478 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 323
TABLE 479 JAPAN: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 323
TABLE 480 JAPAN: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 324
TABLE 481 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 324
TABLE 482 JAPAN: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 325
TABLE 483 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 325
TABLE 484 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 326
TABLE 485 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 326
TABLE 486 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 327
TABLE 487 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 327
TABLE 488 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 328
TABLE 489 SOUTH KOREA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 328
TABLE 490 SOUTH KOREA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 329
TABLE 491 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 329
TABLE 492 SOUTH KOREA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 330
TABLE 493 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 330
TABLE 494 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 331
TABLE 495 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 331
TABLE 496 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 332
TABLE 497 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 332
TABLE 498 INDIA: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 333
TABLE 499 INDIA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 333
TABLE 500 INDIA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 334
TABLE 501 INDIA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 334
TABLE 502 INDIA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 335
TABLE 503 INDIA: ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 335
TABLE 504 INDIA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 336
TABLE 505 INDIA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2035 (USD BILLION) 336
TABLE 506 INDIA: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 337
TABLE 507 INDIA: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 337
TABLE 508 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 338
TABLE 509 AUSTRALIA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 338
TABLE 510 AUSTRALIA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 339
TABLE 511 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 339
TABLE 512 AUSTRALIA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 340
TABLE 513 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 340
TABLE 514 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 341
TABLE 515 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 341
TABLE 516 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 342
TABLE 517 AUSTRALIA: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 342
TABLE 518 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 343
TABLE 519 REST OF ASIA PACIFIC: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 343
TABLE 520 REST OF ASIA PACIFIC: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 344
TABLE 521 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 344
TABLE 522 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 345
TABLE 523 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 345
TABLE 524 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 346
TABLE 525 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 346
TABLE 526 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 347
TABLE 527 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 347
TABLE 528 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY COUNTRY, 2024–2035 (USD BILLION) 348
TABLE 529 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 348
TABLE 530 LATIN AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 349
TABLE 531 LATIN AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 349
TABLE 532 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 350
TABLE 533 LATIN AMERICA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 350
TABLE 534 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 351
TABLE 535 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 351
TABLE 536 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 351
TABLE 537 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 352
TABLE 538 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 352
TABLE 539 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 353
TABLE 540 BRAZIL: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 353
TABLE 541 BRAZIL: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 354
TABLE 542 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 354
TABLE 543 BRAZIL: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 355
TABLE 544 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 355
TABLE 545 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 356
TABLE 546 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 356
TABLE 547 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 357
TABLE 548 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 357
TABLE 549 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 358
TABLE 550 MEXICO: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 358
TABLE 551 MEXICO: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 359
TABLE 552 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 359
TABLE 553 MEXICO: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 360
TABLE 554 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 360
TABLE 555 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 361
TABLE 556 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 361
TABLE 557 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 362
TABLE 558 MEXICO: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 362
TABLE 559 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 363
TABLE 560 REST OF LATIN AMERICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 363
TABLE 561 REST OF LATIN AMERICA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 364
TABLE 562 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 364
TABLE 563 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 365
TABLE 564 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 365
TABLE 565 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 366
TABLE 566 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 366
TABLE 567 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 367
TABLE 568 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 367
TABLE 569 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY SUBREGION, 2024–2035 (USD BILLION) 368
TABLE 570 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 368
TABLE 571 MIDDLE EAST: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 369
TABLE 572 MIDDLE EAST: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 369
TABLE 573 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 370
TABLE 574 MIDDLE EAST: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 370
TABLE 575 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 371
TABLE 576 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 371
TABLE 577 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 371
TABLE 578 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 372
TABLE 579 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 372
TABLE 580 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY,
2024–2035 (USD BILLION) 373
TABLE 581 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 373
TABLE 582 GCC COUNTRIES: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 373
TABLE 583 GCC COUNTRIES: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 374
TABLE 584 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 374
TABLE 585 GCC COUNTRIES: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 375
TABLE 586 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 375
TABLE 587 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 376
TABLE 588 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 376
TABLE 589 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 377
TABLE 590 GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 377
TABLE 591 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 378
TABLE 592 SAUDI ARABIA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 378
TABLE 593 SAUDI ARABIA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 379
TABLE 594 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 379
TABLE 595 SAUDI ARABIA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 380
TABLE 596 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 380
TABLE 597 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 381
TABLE 598 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 381
TABLE 599 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 382
TABLE 600 SAUDI ARABIA: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 382
TABLE 601 UAE: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 383
TABLE 602 UAE: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 383
TABLE 603 UAE: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 384
TABLE 604 UAE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2024–2035 (USD BILLION) 384
TABLE 605 UAE: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 385
TABLE 606 UAE: ANTIBODY THERAPEUTICS MARKET, BY TARGET, 2024–2035 (USD BILLION) 385
TABLE 607 UAE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024–2035 (USD BILLION) 386
TABLE 608 UAE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2035 (USD BILLION) 386
TABLE 609 UAE: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 387
TABLE 610 UAE: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 387
TABLE 611 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 388
TABLE 612 REST OF GCC COUNTRIES: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 388
TABLE 613 REST OF GCC COUNTRIES: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 389
TABLE 614 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 389
TABLE 615 REST OF GCC COUNTRIES: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 390
TABLE 616 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 390
TABLE 617 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 391
TABLE 618 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 391
TABLE 619 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 392
TABLE 620 REST OF GCC COUNTRIES: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 392
TABLE 621 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY PRODUCT, 2024–2035 (USD BILLION) 393
TABLE 622 REST OF MIDDLE EAST: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 393
TABLE 623 REST OF MIDDLE EAST: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 393
TABLE 624 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY FORMAT, 2024–2035 (USD BILLION) 394
TABLE 625 REST OF MIDDLE EAST: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 394
TABLE 626 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY TARGET, 2024–2035 (USD BILLION) 395
TABLE 627 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY SOURCE, 2024–2035 (USD BILLION) 395
TABLE 628 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 395
TABLE 629 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY THERAPEUTIC AREA, 2024–2035 (USD BILLION) 396
TABLE 630 REST OF MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET,
BY END USER, 2024–2035 (USD BILLION) 396
TABLE 631 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY PRODUCT,
2024–2035 (USD BILLION) 397
TABLE 632 AFRICA: COMMERCIALIZED ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 397
TABLE 633 AFRICA: PIPELINE ANTIBODY PRODUCTS MARKET,
BY TYPE, 2024–2035 (USD BILLION) 398
TABLE 634 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT,
2024–2035 (USD BILLION) 398
TABLE 635 AFRICA: ANTIBODY DRUG CONJUGATES (ADCS) MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD BILLION) 399
TABLE 636 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY TARGET,
2024–2035 (USD BILLION) 399
TABLE 637 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE,
2024–2035 (USD BILLION) 400
TABLE 638 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2035 (USD BILLION) 400
TABLE 639 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA,
2024–2035 (USD BILLION) 401
TABLE 640 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY END USER,
2024–2035 (USD BILLION) 401
TABLE 641 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET 402
TABLE 642 DEGREE OF COMPETITION: ANTIBODY THERAPEUTICS MARKET 405
TABLE 643 ANTIBODY THERAPEUTICS MARKET: REGION FOOTPRINT 409
TABLE 644 ANTIBODY THERAPEUTICS MARKET: FORMAT FOOTPRINT 410
TABLE 645 ANTIBODY THERAPEUTICS MARKET: SOURCE FOOTPRINT 411
TABLE 646 ANTIBODY THERAPEUTICS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 412
TABLE 647 ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 415
TABLE 648 ANTIBODY THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SMES 416
TABLE 649 ANTIBODY THERAPEUTICS MARKET: PRODUCT APPROVALS,
JANUARY 2023–JULY 2026 419
TABLE 650 ANTIBODY THERAPEUTICS MARKET: DEALS, JANUARY 2023–JULY 2026 420
TABLE 651 ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2023–JULY 2026 420
TABLE 652 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 421
TABLE 653 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 423
TABLE 654 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 424
TABLE 655 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JULY 2026 425
TABLE 656 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–JULY 2026 426
TABLE 657 ABBVIE INC.: COMPANY OVERVIEW 427
TABLE 658 ABBVIE INC.: PRODUCTS OFFERED 429
TABLE 659 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 429
TABLE 660 ABBVIE INC.: DEALS, JANUARY 2023–JULY 2026 430
TABLE 661 ABBVIE INC.: EXPANSIONS, JANUARY 2023–JULY 2026 431
TABLE 662 AMGEN INC.: COMPANY OVERVIEW 432
TABLE 663 AMGEN INC.: PRODUCTS OFFERED 434
TABLE 664 AMGEN INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 434
TABLE 665 AMGEN INC.: DEALS, JANUARY 2023–JULY 2026 435
TABLE 666 AMGEN INC.: EXPANSIONS, JANUARY 2023–JULY 2026 436
TABLE 667 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW 437
TABLE 668 REGENERON PHARMACEUTICALS, INC.: PRODUCTS OFFERED 438
TABLE 669 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS,
JANUARY 2023–JULY 2026 439
TABLE 670 REGENERON PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–JULY 2026 439
TABLE 671 REGENERON PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 440
TABLE 672 ASTRAZENECA PLC: COMPANY OVERVIEW 441
TABLE 673 ASTRAZENECA PLC: PRODUCTS OFFERED 442
TABLE 674 ASTRAZENECA PLC: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 443
TABLE 675 ASTRAZENECA PLC: DEALS, JANUARY 2023–JULY 2026 443
TABLE 676 ASTRAZENECA PLC: EXPANSIONS, JANUARY 2023–JULY 2026 444
TABLE 677 BIOGEN INC.: COMPANY OVERVIEW 445
TABLE 678 BIOGEN INC.: PRODUCTS OFFERED 447
TABLE 679 BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 447
TABLE 680 BIOGEN INC.: DEALS, JANUARY 2023–JULY 2026 448
TABLE 681 BIOGEN INC.: EXPANSIONS, JANUARY 2023–JULY 2026 448
TABLE 682 MERCK & CO., INC.: COMPANY OVERVIEW 450
TABLE 683 MERCK & CO., INC.: PRODUCTS OFFERED 451
TABLE 684 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 452
TABLE 685 MERCK & CO., INC.: DEALS, JANUARY 2023–JULY 2026 452
TABLE 686 NOVARTIS AG: COMPANY OVERVIEW 454
TABLE 687 NOVARTIS AG: PRODUCTS OFFERED 455
TABLE 688 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 456
TABLE 689 NOVARTIS AG: DEALS, JANUARY 2023–JULY 2026 456
TABLE 690 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 457
TABLE 691 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 459
TABLE 692 DAIICHI SANKYO COMPANY, LIMITED: PRODUCT APPROVALS,
JANUARY 2023–JULY 2026 459
TABLE 693 DAIICHI SANKYO COMPANY, LIMITED: DEALS, JANUARY 2023–JULY 2026 460
TABLE 694 GSK PLC: COMPANY OVERVIEW 461
TABLE 695 GSK PLC: PRODUCTS OFFERED 462
TABLE 696 GSK PLC: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 463
TABLE 697 SANOFI: COMPANY OVERVIEW 464
TABLE 698 SANOFI : PRODUCTS OFFERED 465
TABLE 699 SANOFI: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 466
TABLE 700 SANOFI: DEALS, JANUARY 2023–JULY 2026 466
TABLE 701 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 467
TABLE 702 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 468
TABLE 703 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 469
TABLE 704 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW 470
TABLE 705 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED 471
TABLE 706 JAZZ PHARMACEUTICALS PLC: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 472
TABLE 707 JAZZ PHARMACEUTICALS PLC: DEALS, JANUARY 2023–JULY 2026 472
TABLE 708 PFIZER INC.: COMPANY OVERVIEW 473
TABLE 709 PFIZER INC.: PRODUCTS OFFERED 474
TABLE 710 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 475
TABLE 711 PFIZER INC.: DEALS, JANUARY 2023–JULY 2026 475
TABLE 712 JOHNSON & JOHNSON: COMPANY OVERVIEW 476
TABLE 713 JOHNSON & JOHNSON: PRODUCTS OFFERED 477
TABLE 714 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 478
TABLE 715 JOHNSON & JOHNSON: DEALS, JANUARY 2023–JULY 2026 478
TABLE 716 ELI LILLY AND COMPANY: COMPANY OVERVIEW 479
TABLE 717 ELI LILLY AND COMPANY: PRODUCTS OFFERED 480
TABLE 718 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 481
TABLE 719 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2023–JULY 2026 481
TABLE 720 H. LUNDBECK A/S: COMPANY OVERVIEW 482
TABLE 721 H. LUNDBECK A/S: PRODUCTS OFFERED 483
TABLE 722 H. LUNDBECK A/S: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 483
TABLE 723 CHUGAI PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 484
TABLE 724 AKESO, INC.: COMPANY OVERVIEW 485
TABLE 725 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 486
TABLE 726 CELLTRION, INC.: COMPANY OVERVIEW 488
TABLE 727 CSL BEHRING: COMPANY OVERVIEW 489
TABLE 728 OTSUKA AMERICA PHARMACEUTICAL, INC.: COMPANY OVERVIEW 490
TABLE 729 LEPU BIOPHARMA CO., LTD.: COMPANY OVERVIEW 491
TABLE 730 SINOCELLTECH GROUP LTD.: COMPANY OVERVIEW 492
TABLE 731 SYNERMORE BIOLOGICS: COMPANY OVERVIEW 493
TABLE 732 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: COMPANY OVERVIEW 494
TABLE 733 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 495
TABLE 734 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 505
FIGURE 1 ANTIBODY THERAPEUTICS MARKET SEGMENTATION & REGIONS COVERED 47
FIGURE 2 ANTIBODY THERAPEUTICS MARKET: YEARS CONSIDERED 48
FIGURE 3 MARKET SCENARIO 51
FIGURE 4 GLOBAL ANTIBODY THERAPEUTICS MARKET, 2024–2035 52
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET, 2023–2026 52
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF ANTIBODY THERAPEUTICS MARKET 53
FIGURE 7 HIGH-GROWTH SEGMENTS IN ANTIBODY THERAPEUTICS MARKET, 2026–2031 54
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN ANTIBODY THERAPEUTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 55
FIGURE 9 RISING CLINICAL SUCCESS AND REGULATORY APPROVALS OF ANTIBODY THERAPEUTICS TO BOOST MARKET GROWTH 56
FIGURE 10 INTRAVENOUS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE
IN NORTH AMERICA IN 2025 57
FIGURE 11 JAPAN TO REGISTER SIGNIFICANT CAGR DURING FORECAST PERIOD 58
FIGURE 12 HUMANIZED ANTIBODIES TO DOMINATE MARKET DURING FORECAST PERIOD 58
FIGURE 13 GLOBAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
FIGURE 14 GLOBAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 15 GLOBAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS 69
FIGURE 16 GLOBAL ANTIBODY THERAPEUTICS MARKET: ECOSYSTEM ANALYSIS 71
FIGURE 17 GLOBAL ANTIBODY THERAPEUTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
FIGURE 18 IMPACT OF AI ON THE GLOBAL ANTIBODY THERAPEUTICS MARKET 86
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 100
FIGURE 20 KEY BUYING CRITERIA, BY END USER 100
FIGURE 21 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET SNAPSHOT 261
FIGURE 22 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET SNAPSHOT 312
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY THERAPEUTICS
MARKET, 2023–2025 404
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET, 2025 405
FIGURE 25 ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 407
FIGURE 26 ANTIBODY THERAPEUTICS MARKET: COMPANY FOOTPRINT 408
FIGURE 27 ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 414
FIGURE 28 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 417
FIGURE 29 EV/EBITDA OF KEY VENDORS 417
FIGURE 30 ANTIBODY THERAPEUTICS MARKET: BRAND/PRODUCT COMPARISON 418
FIGURE 31 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 422
FIGURE 32 ABBVIE INC.: COMPANY SNAPSHOT (2025) 428
FIGURE 33 AMGEN INC.: COMPANY SNAPSHOT (2025) 433
FIGURE 34 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 437
FIGURE 35 ASTRAZENECA: COMPANY SNAPSHOT (2025) 441
FIGURE 36 BIOGEN INC.: COMPANY SNAPSHOT (2025) 446
FIGURE 37 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 451
FIGURE 38 NOVARTIS AG: COMPANY SNAPSHOT (2025) 455
FIGURE 39 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025) 458
FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025) 462
FIGURE 41 SANOFI: COMPANY SNAPSHOT (2025) 465
FIGURE 42 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025) 468
FIGURE 43 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 471
FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2025) 474
FIGURE 45 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2025) 477
FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 480
FIGURE 47 H. LUNDBECK A/S: COMPANY SNAPSHOT (2025) 482
FIGURE 48 RESEARCH DESIGN 497
FIGURE 49 ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 499
FIGURE 50 ANTIBODY THERAPEUTICS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2025 500
FIGURE 51 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 501
FIGURE 52 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF
F. HOFFMANN-LA ROCHE (2025) 501
FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 502
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 503
FIGURE 55 ANTIBODY THERAPEUTICS MARKET CAGR PROJECTIONS: 504
FIGURE 56 DATA TRIANGULATION METHODOLOGY 506
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們